Rapport Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Rapport Therapeutics, Inc. (RAPP) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- Rapport Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $595.00K, a 23.19% increase year-over-year.
- Rapport Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $582.00K, a 41.61% increase year-over-year.
- Rapport Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $571.00K, a 246.06% increase year-over-year.
- Rapport Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $567.00K, a 250.00% increase year-over-year.
- Rapport Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $2.03M, a 216.51% increase from fiscal 2024.
- Rapport Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $642.00K, a 211.65% increase from fiscal 2023.
- Rapport Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $206.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $595.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.18M 10-Q · filed 2026-08-05 | $1.75M derived: sum of 3 quarters · filed 2026-08-05 | $2.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $582.00K 10-Q · filed 2026-05-07 | $1.15M derived: sum of 2 quarters · filed 2026-05-07 | $1.72M derived: sum of 3 quarters · filed 2026-05-07 | $2.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $571.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.14M derived: sum of 2 quarters · filed 2026-03-10 | $1.62M derived: sum of 3 quarters · filed 2026-08-05 | $2.03M 10-K · filed 2026-03-10 |
| 2025-09-30 | $567.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.05M derived: sum of 2 quarters · filed 2026-08-05 | $1.46M 10-Q · filed 2025-11-06 | $1.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $483.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $894.00K 10-Q · filed 2026-08-05 | $1.06M derived: sum of 3 quarters · filed 2026-08-05 | $1.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $411.00K 10-Q · filed 2026-05-07 | $576.00K derived: sum of 2 quarters · filed 2026-05-07 | $738.00K derived: sum of 3 quarters · filed 2026-05-07 | $897.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $327.00K derived: sum of 2 quarters · filed 2026-03-10 | $486.00K derived: sum of 3 quarters · filed 2026-03-10 | $642.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $162.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $321.00K derived: sum of 2 quarters · filed 2025-11-06 | $477.00K 10-Q · filed 2025-11-06 | $631.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $315.00K 10-Q · filed 2025-08-07 | $469.00K derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | $156.00K 10-Q · filed 2025-05-08 | $310.00K derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $206.00K 10-K · filed 2025-03-11 | ||
| 2023-09-30 | $52.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |